These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27052572)

  • 1. Designing therapeutic cancer vaccines by mimicking viral infections.
    Sultan H; Fesenkova VI; Addis D; Fan AE; Kumai T; Wu J; Salazar AM; Celis E
    Cancer Immunol Immunother; 2017 Feb; 66(2):203-213. PubMed ID: 27052572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses.
    Kumai T; Lee S; Cho HI; Sultan H; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2017 Jan; 5(1):72-83. PubMed ID: 27941004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes.
    Eggert AO; Andersen MH; Voigt H; Schrama D; Kämpgen E; Straten PT; Becker JC
    Eur J Immunol; 2004 Nov; 34(11):3285-90. PubMed ID: 15384049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome.
    Voskens CJ; Strome SE; Sewell DA
    Curr Mol Med; 2009 Aug; 9(6):683-93. PubMed ID: 19689295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines.
    Varypataki EM; Benne N; Bouwstra J; Jiskoot W; Ossendorp F
    Cancer Immunol Res; 2017 Mar; 5(3):222-233. PubMed ID: 28143806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Composite peptide-based vaccines for cancer immunotherapy (Review).
    Yang J; Zhang Q; Li K; Yin H; Zheng JN
    Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S; Wang F; He X; He Y; Li D; Sun S
    Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide-Based Cancer Vaccine Strategies and Clinical Results.
    Schneble E; Clifton GT; Hale DF; Peoples GE
    Methods Mol Biol; 2016; 1403():797-817. PubMed ID: 27076168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-based vaccines for cancer therapy.
    Parmiani G; Russo V; Maccalli C; Parolini D; Rizzo N; Maio M
    Hum Vaccin Immunother; 2014; 10(11):3175-8. PubMed ID: 25483658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis.
    Wang Q; Klinke DJ; Wang Z
    BMC Syst Biol; 2015 Jun; 9():27. PubMed ID: 26048402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multipeptide vaccination in cancer patients.
    Pilla L; Rivoltini L; Patuzzo R; Marrari A; Valdagni R; Parmiani G
    Expert Opin Biol Ther; 2009 Aug; 9(8):1043-55. PubMed ID: 19591629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide vaccines in breast cancer: The immunological basis for clinical response.
    Peres Lde P; da Luz FA; Pultz Bdos A; Brígido PC; de Araújo RA; Goulart LR; Silva MJ
    Biotechnol Adv; 2015 Dec; 33(8):1868-77. PubMed ID: 26523780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid induces dose-dependent increase of antigen-specific CD8 T-cell responses in combination with peptide/poly-IC vaccine.
    Park HM; Cho HI; Shin CA; Shon HJ; Kim TG
    Vaccine; 2016 Mar; 34(10):1275-81. PubMed ID: 26828454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel multi-epitope peptide vaccine against cancer: an in silico approach.
    Nezafat N; Ghasemi Y; Javadi G; Khoshnoud MJ; Omidinia E
    J Theor Biol; 2014 May; 349():121-34. PubMed ID: 24512916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma.
    Ly LV; Sluijter M; van der Burg SH; Jager MJ; van Hall T
    J Immunol; 2013 Jan; 190(1):489-96. PubMed ID: 23203930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide vaccines against cancer, infectious diseases, and conception.
    Naz RK; Dabir P
    Front Biosci; 2007 Jan; 12():1833-44. PubMed ID: 17127424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.
    Melief CJ; van der Burg SH
    Nat Rev Cancer; 2008 May; 8(5):351-60. PubMed ID: 18418403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
    Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
    Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.